Triomics is a generative AI platform purpose-built for oncology workflows, transforming how cancer centers process and utilize patient data. The company, founded in 2021, operates in the United States and has secured $37 million in funding. Its core technical domains are Generative AI, Large Language Models, and Oncology Informatics.
The company's product, OncoLLM, is a specialized large language model designed to reason across entire longitudinal patient records, which can span hundreds of pages and years of care. Rather than processing documents individually, the model delivers structured, cited answers with expert-level accuracy directly into the electronic medical record workflows used by cancer centers.
Triomics reports processing over 120,000 charts monthly and screening more than 65,000 patients for clinical trials each month. Its customer base includes four of the top ten cancer centers in the United States.
